Bharat Biotech India covid-19 vaccine Provident Bharat Biotech India

Covaxin meets WHO efficacy criteria for Covid vaccines for Delta variant: Bharat Biotech

Reading now: 721

Covaxin. "These results compare well with the 65.2% efficacy against the delta variant obtained during the controlled phase III clinical trials of Covaxin conducted among the general population.

This study also shows that Covaxin meets the WHO efficacy criteria for Covid-19 vaccines for the dreaded Delta variant," the company said.

The development of the country's indigenous COVID-19 vaccine Covaxin is a true success story for public-private partnerships in India, which is based on mutual respect, trust and transparency, said Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News